Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bicycle Therapeutics raises £40mm through Series B round; second tranche closed

Executive Summary

Bicycle Therapeutics Ltd. closed its Series B round, raising £40mm ($52mm) from new investors Vertex Ventures HC (lead), Cambridge Innovation Capital, and Longwood Fund, along with returning backers Novartis Venture Fund, SR One, SV Life Sciences, and Atlas Venture. (Vertex and Cambridge join the board.) Bicycle is developing cancer therapies based on its Bicycles bicyclic peptide platform, and will use the proceeds to advance development of lead preclinical candidate BT1718 for triple-negative breast cancer and non-small cell lung cancer, and to continue studies on additional pipeline projects.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies